Healthcare / Medical DevicesTSXV
$0.06
-0.00 (-8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18M
P/E
N/A
•EV/EBITDA
N/A
•ROE
64.6%
↑Gross Margin
31.2%
↓Debt/Equity
-0.82
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.5%
FCF CAGR
—
FCF margin
-788.6%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $473266.0 · net income $-6.3M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $473266.00 | $473266.00 | $489698.00 | $456088.00 | $510606.00 |
| Net Income | $-6.3M | $-6.3M | $-3.7M | $-4.6M | $-5.1M |
| EBITDA | $-4.5M | $-4.5M | $-2.3M | $-2.4M | $-3.8M |
| EPS | -0.02 | -0.02 | -0.01 | -0.02 | -0.03 |
| Gross Margin | 31.2% | 31.2% | 39.7% | 40.7% | 47.0% |
| Operating Margin | -906.9% | -906.9% | -470.4% | -664.0% | -757.6% |
| Net Margin | -1329.2% | -1329.2% | -746.0% | -1004.3% | -1005.4% |
| Balance Sheet | |||||
| Debt/Equity | -0.82 | -0.82 | -0.82 | -0.82 | -0.71 |
| Current Ratio | 0.04 | 0.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-2.5M | $-3.4M | $-2.8M |
| Returns | |||||
| ROE | 64.6% | 64.6% | 42.9% | 64.1% | 72.5% |
| Growth & Yield | |||||
| Revenue Growth | -3.4% | -3.4% | 7.4% | -10.7% | — |
| EPS Growth | -100.0% | -100.0% | 50.0% | 33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.02
Residual
-38.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.